The above evidence demonstrated that the LCRC prognostic signature consisting of NOS2 and IFNG and the 2-gene signature of RCRC based on NOS2 and ALOXE3 were able to predict clinical outcomes in CRC patients with tolerable confidence. This evidence concerns the gene ALOXE3 and colorectal carcinoma.